Stevanato Group posted third-quarter revenue of €326 million, an 8% increase from the prior year period, driven by 11% organic growth in its Biopharmaceutical and Diagnostic Solutions segment which offset a 12% decline in Engineering. Adjusted EBITDA rose 14% to €88.8 million, expanding margins by 150 basis points to 27.2%, while adjusted diluted EPS reached €0.16. The company reiterated its full-year revenue guidance of €1.26 billion to €1.28 billion but lowered expectations for the Engineering segment and noted that lower-than-anticipated GLP-1 volumes will temporarily moderate growth in fiscal 2027, a decline expected to be backfilled by strong biologics demand. Stevanato Group manufactures primary packaging solutions and drug delivery systems for the pharmaceutical industry.
